Literature DB >> 18798534

Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium.

Melissa L Bondy1, Michael E Scheurer, Beatrice Malmer, Jill S Barnholtz-Sloan, Faith G Davis, Dora Il'yasova, Carol Kruchko, Bridget J McCarthy, Preetha Rajaraman, Judith A Schwartzbaum, Siegal Sadetzki, Brigitte Schlehofer, Tarik Tihan, Joseph L Wiemels, Margaret Wrensch, Patricia A Buffler.   

Abstract

Epidemiologists in the Brain Tumor Epidemiology Consortium (BTEC) have prioritized areas for further research. Although many risk factors have been examined over the past several decades, there are few consistent findings, possibly because of small sample sizes in individual studies and differences between studies in patients, tumor types, and methods of classification. Individual studies generally have lacked samples of sufficient size to examine interactions. A major priority based on available evidence and technologies includes expanding research in genetics and molecular epidemiology of brain tumors. BTEC has taken an active role in promoting understudied groups, such as pediatric brain tumors; the etiology of rare glioma subtypes, such as oligodendroglioma; and meningioma, which, although it is not uncommon, has only recently been registered systematically in the United States. There also is a pressing need for more researchers, especially junior investigators, to study brain tumor epidemiology. However, relatively poor funding for brain tumor research has made it difficult to encourage careers in this area. In this report, BTEC epidemiologists reviewed the group's consensus on the current state of scientific findings, and they present a consensus on research priorities to identify which important areas the science should move to address.

Entities:  

Mesh:

Year:  2008        PMID: 18798534      PMCID: PMC2861559          DOI: 10.1002/cncr.23741

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  174 in total

1.  A comparative survival evaluation and assessment of interclassification concordance in adult supratentorial astrocytic tumors.

Authors:  A K Karak; R Singh; P N Tandon; C Sarkar
Journal:  Pathol Oncol Res       Date:  2000       Impact factor: 3.201

2.  Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas.

Authors:  J S Smith; A Perry; T J Borell; H K Lee; J O'Fallon; S M Hosek; D Kimmel; A Yates; P C Burger; B W Scheithauer; R B Jenkins
Journal:  J Clin Oncol       Date:  2000-02       Impact factor: 44.544

Review 3.  Pharmacogenetics in cancer treatment.

Authors:  R Nagasubramanian; F Innocenti; M J Ratain
Journal:  Annu Rev Med       Date:  2001-12-03       Impact factor: 13.739

4.  Different aetiology of familial low-grade and high-grade glioma? A nationwide cohort study of familial glioma.

Authors:  Beatrice Malmer; Roger Henriksson; Henrik Grönberg
Journal:  Neuroepidemiology       Date:  2002 Nov-Dec       Impact factor: 3.282

5.  Homozygosity mapping of familial glioma in Northern Sweden.

Authors:  Beatrice Malmer; Susann Haraldsson; Elisabet Einarsdottir; Petter Lindgren; Dan Holmberg
Journal:  Acta Oncol       Date:  2005       Impact factor: 4.089

6.  Risk of nervous system cancer among workers exposed to lead.

Authors:  A Anttila; P Heikkilä; E Nykyri; T Kauppinen; E Pukkala; S Hernberg; K Hemminki
Journal:  J Occup Environ Med       Date:  1996-02       Impact factor: 2.162

7.  Environmental exposure to cadmium and risk of cancer: a prospective population-based study.

Authors:  Tim Nawrot; Michelle Plusquin; Janneke Hogervorst; Harry A Roels; Hilde Celis; Lutgarde Thijs; Jaco Vangronsveld; Etienne Van Hecke; Jan A Staessen
Journal:  Lancet Oncol       Date:  2006-02       Impact factor: 41.316

8.  Positive and negative associations of human leukocyte antigen variants with the onset and prognosis of adult glioblastoma multiforme.

Authors:  Jianming Tang; Wenshuo Shao; M Tevfik Dorak; Yufeng Li; Rei Miike; Elena Lobashevsky; John K Wiencke; Margaret Wrensch; Richard A Kaslow; Charles S Cobbs
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-08       Impact factor: 4.254

9.  Longitudinal changes in cognition and behavior in asymptomatic carriers of the APOE e4 allele.

Authors:  R J Caselli; E M Reiman; D Osborne; J G Hentz; L C Baxter; J L Hernandez; G G Alexander
Journal:  Neurology       Date:  2004-06-08       Impact factor: 9.910

Review 10.  Molecular and cellular mechanisms of cadmium carcinogenesis.

Authors:  Michael Waisberg; Pius Joseph; Beverley Hale; Detmar Beyersmann
Journal:  Toxicology       Date:  2003-11-05       Impact factor: 4.221

View more
  292 in total

1.  Survey of familial glioma and role of germline p16INK4A/p14ARF and p53 mutation.

Authors:  Lindsay B Robertson; Georgina N Armstrong; Bianca D Olver; Amy L Lloyd; Sanjay Shete; Ching Lau; Elizabeth B Claus; Jill Barnholtz-Sloan; Rose Lai; Dora Il'yasova; Joellen Schildkraut; Jonine L Bernstein; Sara H Olson; Robert B Jenkins; Ping Yang; Amanda Lynn Rynearson; Amanda L Rynerason; Margaret Wrensch; Lucie McCoy; John K Wienkce; Bridget McCarthy; Faith Davis; Nicholas A Vick; Christoffer Johansen; Hanne Bødtcher; Siegal Sadetzki; Revital Bar-Sade Bruchim; Galit Hirsh Yechezkel; Ulrika Andersson; Beatrice S Melin; Melissa L Bondy; Richard S Houlston
Journal:  Fam Cancer       Date:  2010-09       Impact factor: 2.375

2.  Possible association between genetic variants in the H2AFX promoter region and risk of adult glioma in a Chinese Han population.

Authors:  Weiwei Fan; Keke Zhou; Yingjie Zhao; Wenting Wu; Hongyan Chen; Li Jin; Gong Chen; Jinlong Shi; Qingyi Wei; Tianbao Zhang; Guhong Du; Ying Mao; Daru Lu; Liangfu Zhou
Journal:  J Neurooncol       Date:  2011-04-22       Impact factor: 4.130

3.  Selected human leukocyte antigen class II polymorphisms and risk of adult glioma.

Authors:  Bryan A Bassig; Peter D Inskip; Laurie Burdette; William R Shapiro; Robert G Selker; Howard A Fine; Jay S Loeffler; Peter M Black; Robert Dubrow; Alina V Brenner
Journal:  J Neuroimmunol       Date:  2010-12-30       Impact factor: 3.478

4.  Allergy and glioma risk: test of association by genotype.

Authors:  Sara E Dobbins; Fay J Hosking; Sanjay Shete; Georgina Armstrong; Anthony Swerdlow; Yanhong Liu; Robert Yu; Ching Lau; Minouk J Schoemaker; Sarah J Hepworth; Kenneth Muir; Melissa Bondy; Richard S Houlston
Journal:  Int J Cancer       Date:  2010-05-25       Impact factor: 7.396

Review 5.  Strategies to target drugs to gliomas and CNS metastases of solid tumors.

Authors:  B Milojkovic Kerklaan; O van Tellingen; A D R Huitema; J H Beijnen; W Boogerd; J H M Schellens; D Brandsma
Journal:  J Neurol       Date:  2015-10-17       Impact factor: 4.849

6.  Association of BCL2-938C>A genetic polymorphism with glioma risk in Chinese Han population.

Authors:  Wei Li; Chunfa Qian; Linxiong Wang; Hong Teng; Li Zhang
Journal:  Tumour Biol       Date:  2013-11-28

7.  Cancers of the brain and CNS: global patterns and trends in incidence.

Authors:  Adalberto Miranda-Filho; Marion Piñeros; Isabelle Soerjomataram; Isabelle Deltour; Freddie Bray
Journal:  Neuro Oncol       Date:  2017-02-01       Impact factor: 12.300

8.  Occupational exposure to metals and risk of meningioma: a multinational case-control study.

Authors:  Siegal Sadetzki; Angela Chetrit; Michelle C Turner; Martie van Tongeren; Geza Benke; Jordi Figuerola; Sarah Fleming; Martine Hours; Laurel Kincl; Daniel Krewski; Dave McLean; Marie-Elise Parent; Lesley Richardson; Brigitte Schlehofer; Klaus Schlaefer; Maria Blettner; Joachim Schüz; Jack Siemiatycki; Elisabeth Cardis
Journal:  J Neurooncol       Date:  2016-09-23       Impact factor: 4.130

Review 9.  Pharmacotherapeutic management of pediatric gliomas : current and upcoming strategies.

Authors:  Trent R Hummel; Lionel M Chow; Maryam Fouladi; David Franz
Journal:  Paediatr Drugs       Date:  2013-02       Impact factor: 3.022

10.  Association Between PARP1 Single Nucleotide Polymorphism and Brain Tumors.

Authors:  Hong Wang; Kun Zhang; Haifeng Qin; Lin Yang; Liyu Zhang; Yanyan Cao
Journal:  Mol Neurobiol       Date:  2015-04-25       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.